Q3 Earnings Estimate for AURA Issued By HC Wainwright

Aura Biosciences, Inc. (NASDAQ:AURA) – Research analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Aura Biosciences in a note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. White anticipates that the company will earn ($0.47) per share for the quarter. HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences’ FY2027 earnings at ($1.64) EPS.

Separately, Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Stock Performance

NASDAQ AURA opened at $5.99 on Wednesday. Aura Biosciences has a fifty-two week low of $5.94 and a fifty-two week high of $12.38. The stock has a market cap of $299.21 million, a P/E ratio of -3.46 and a beta of 0.30. The stock has a 50 day simple moving average of $7.60 and a two-hundred day simple moving average of $8.64.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Monday, March 24th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09).

Institutional Trading of Aura Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP lifted its position in Aura Biosciences by 12.6% during the 4th quarter. Wellington Management Group LLP now owns 131,054 shares of the company’s stock valued at $1,077,000 after acquiring an additional 14,662 shares during the period. ProShare Advisors LLC purchased a new stake in shares of Aura Biosciences in the 4th quarter worth approximately $127,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Aura Biosciences by 27.7% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 136,516 shares of the company’s stock worth $1,122,000 after buying an additional 29,618 shares during the last quarter. Ensign Peak Advisors Inc increased its position in Aura Biosciences by 43.3% during the 4th quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock valued at $3,212,000 after buying an additional 118,000 shares in the last quarter. Finally, Deutsche Bank AG raised its stake in Aura Biosciences by 56.7% during the fourth quarter. Deutsche Bank AG now owns 44,085 shares of the company’s stock valued at $362,000 after buying an additional 15,951 shares during the last quarter. 96.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Aura Biosciences

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares of the company’s stock, valued at approximately $2,336,987.64. This trade represents a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In the last three months, insiders have sold 23,045 shares of company stock valued at $177,242. 5.40% of the stock is currently owned by corporate insiders.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.